Pharvaris (NASDAQ:PHVS) Short Interest Up 25.7% in February

Pharvaris (NASDAQ:PHVS) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 390,900 shares, an increase of 25.7% from the January 31st total of 311,100 shares. Based on an average trading volume of 64,900 shares, the short-interest ratio is presently 6.0 days. Approximately 2.3% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, JMP Securities raised their price objective on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, January 31st.

Institutional Trading of Pharvaris

Large investors have recently made changes to their positions in the business. FMR LLC grew its position in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after acquiring an additional 189,714 shares in the last quarter. Soleus Capital Management L.P. increased its position in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. Octagon Capital Advisors LP raised its holdings in Pharvaris by 25.4% during the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after buying an additional 157,530 shares during the period. Rock Springs Capital Management LP raised its holdings in Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock valued at $14,859,000 after buying an additional 18,200 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after acquiring an additional 118,408 shares during the last quarter.

Pharvaris Stock Down 0.1 %

Pharvaris stock traded down $0.02 during mid-day trading on Thursday, reaching $14.98. 47,964 shares of the company’s stock traded hands, compared to its average volume of 71,497. Pharvaris has a 12-month low of $14.37 and a 12-month high of $27.46. The stock has a 50 day moving average of $17.57 and a two-hundred day moving average of $19.24. The company has a market cap of $783.04 million, a price-to-earnings ratio of -5.35 and a beta of -3.02.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.